(MedPage Today) — Minor issues include a bump in rejections of medical necessity claims
Uncategorized
Aflibercept helps flatten persistent pigment epithelial detachments
Both retinal pigment epithelium height and central subfield thickness were reduced in patients with persistent retinal fluid whose treatment was switched to aflibercept from another intravitreal anti-VEGF, according to a study. Visual acuity, however, …
Uncategorized
Publication Exclusive: Breaking down the sham of statistical significance
What does P
Retina Implant’s Higher Resolution Alpha AMS Visual Implant Cleared in EU
Retina Implant AG, a Reutlingen, Germany firm, obtained European regulatory approval for its Alpha AMS subretinal implant for people that have become blind due to retinitis pigmentosa. The new device is an upgrade to the Alpha IMS that was cleared in Europe back in 2013. The Alpha AMS features 1,600 pixels, which is 100 more than […]
Uncategorized
Ora designates senior director in Europe
Ora has appointed Simon Chandler, PhD, as senior director to lead regulatory and clinical operations for Europe, according to a company press release.He will be based in the U.K.
Uncategorized
ThromboGenics reports €37.9 million net loss in 2015
ThromboGenics reported a net loss of €37.9 million, or €1.05 per share, in 2015 compared with €51.1 million, or €1.42 per share, in 2014, according to a company press release. Total revenue was reported at €11.2 million in 2015, which included €7.4 million in Jetrea sales in the U.S. and €3.2 million in royalties from Alcon based on sales of Jetrea outside the U.S.